Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation

Wuhan University2,040 enrolled

Overview

To compare the efficacy of different procedures, identify the optimal procedure, ablation sites, ablation endpoints and post-operative anticoagulation strategy, establish the optimal treatment strategy for atrial fibrillation.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,040

Conditions

Atrial Fibrillation

Interventions

catheter ablationPROCEDURE

circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Atrial fibrillation recorded by ECG or Holter; 2. Age: 18 \~ 75 years; 3. Patients who are willing to enroll in the trial Exclusion Criteria: 1. Patients accompanied hyperthyroidism; 2. Patients with sever liver or renal dysfunction; 3. Patients with sever cardiac dysfunction; 4. Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure; 5. Patients with emboli in atrium; 6. Pregnant woman

Locations (1)

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

recurrence of atrial arrhythmias (AF, AFL, AT)

Time frame: 1 month

recurrence of atrial arrhythmias (AF, AFL, AT)

Time frame: 3 month

recurrence of atrial arrhythmias (AF, AFL, AT)

Time frame: 6 month

recurrence of atrial arrhythmias (AF, AFL, AT)

Time frame: 12 month

Secondary Outcomes

Number of participants with all-cause death

Time frame: 1 month

Number of participants with all-cause death

Time frame: 3 month

Number of participants with all-cause death

Time frame: 6 month

Number of participants with all-cause death

Time frame: 12 month

severe blooding complications

Time frame: 1 month

severe blooding complications

Time frame: 3 month

severe blooding complications

Time frame: 6 month

severe blooding complications

Time frame: 12 month

cardio-cerebrovascular complications

Central Contacts

Cong-xin Huang, doctor

CONTACT

13907131546 huangcongxin@yahoo.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.